The same fully implanted, wireless device supporting motor recovery after stroke now enables thought-controlled computer use without additional surgery or hardware. Freiburg, Germany, April 29, 2026 – CorTec GmbH today announced that the first participant in the University of Washington’s NIH-funded clinical trial of the Brain Interchange™ BCI system has successfully controlled a computer […]
Freiburg, Germany, April 23, 2026 – CorTec GmbH today announced that the U.S. Food and Drug Administration (FDA) has accepted the company into its Total Product Life Cycle Advisory Program (TAP), recognizing the Brain Interchange™ BCI system as a priority innovation in stroke motor rehabilitation. The TAP enrollment follows the recently granted FDA Breakthrough Device
Second implantation at Harborview Medical Center in Seattle marks continued progress in the FDA-approved study informed by promising results from the first participant. Freiburg, Germany, February 10, 2026 – CorTec GmbH, a pioneer in active implantable medical technologies, today announced the successful second implantation of its proprietary BrainComputer Interface (BCI) system, the Brain Interchange™, in
Looking back, 2025 has been a truly remarkable year for CorTec, filled with milestones, inspiring collaborations, and unforgettable moments. Early in the year, we entered into a strategic partnership with Heraeus Medevio. Together combine our strengths in development, prototyping, small series production and large series production. This way both companies create scalable, high-quality solutions,
The closed-loop BCI system, developed entirely in Germany, is currently being evaluated in an FDA-approved clinical trial with stroke patients at Harborview Medical Center in Seattle, a part of UW Medicine Freiburg, Germany, July 29, 2025 – CorTec GmbH, a pioneer in active implantable medical technologies, today announced the first human implantation of its
CorTec’s fully implantable Brain-Computer Interface (BCI) system has reached clinical readiness, and we are in preparation for the next milestone on our journey – the first in human implantation. The system is based on a modular platform that enables flexible use across a range of neurotechnological applications. With high-resolution signal processing and bidirectional communication, the
Our Brain Interchange BCI System Reaches Clinical Readiness Read More »
FEATURE
Recording channels
Sampling rate
Sampling dynamic range
High pass filter cut-off
Low pass filter cut-off
Amplifier band pass gain
Band pass roll-off
Reference
Stimulation
Stimulation channels
Current
Current source
Pulse width
Power supply
Wireless data transmission
Closed Loop latency
VALUE
32
1 kHz
16 bit (74 nV smallest increment)
ca. 2 Hz
325 Hz
Adjustable: 100-750
20 dB/dec
Any (subset) of the recording channels selectable by software or one dedicated hard-wired additional contact
Current-controlled, biphasic, rectangular, asymmetric stimulus pulses (cathodic amplitude with pulse width followed by an anodic counter pulse of 1/4x amplitude and 4x pulse width)
32
Max. -6 mA / +1.5 mA (24 µA increments) within
compliance voltage range of -11 V to +5 V
Can be directed to any of the 32 electrode contacts
Negative phase: 10 µs – 2,500 µs
Wireless inductive, 120-140 kHz
Bi-directional, radio frequency in 2400-2483.5 MHz band ≤ 40 ms
We’re happy to help you realize your next project. Whether it is a complete implantable system design, an electrode or another component.
Please fill out the form below and our sales team will be in contact with you shortly.